Lyra Therapeutics, Inc. — Director's Dealing 2021

Jun 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyra Therapeutics, Inc. (LYRA)
CIK: 0001327273
Period of Report: 2021-06-17

Reporting Person: MERRIFIELD C ANN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-17	Common Stock	P	3500	$8.9699	Acquired	3500	Direct